首页>
美国卫生研究院文献>Frontiers in Pharmacology
>Therapeutic Efficacy and Safety of Traditional Chinese Medicine Classic Herbal Formula Longdanxiegan Decoction for Hypertension: A Systematic Review and Meta-Analysis
【2h】
Therapeutic Efficacy and Safety of Traditional Chinese Medicine Classic Herbal Formula Longdanxiegan Decoction for Hypertension: A Systematic Review and Meta-Analysis
Background: The traditional Chinese medicine classic herbal formula Longdanxiegan decoction (LDXGD) is widely used for hypertensive patients in China.Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of LDXGD for hypertension.Methods: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, Chinese National Knowledge Infrastructure, and Wanfang Database were searched up to February 7, 2017 for randomized control trials in treating hypertension.Results: Nine trials were identified. Compared with antihypertensive drugs, Longdanxiegan decoction plus antihypertensive drugs (LPAD) significantly improved systolic blood pressure (BP) (n = 138; MD = −4.82 mmHg; 95% CI: −7.89 to −1.76; P = 0.002), diastolic BP (n = 138; MD = −2.42 mmHg; 95% CI: −3.22 to −1.62; P < 0.00001), categorical BP (n = 509; RR: 1.26; 95% CI: 1.17 to 1.36; P < 0.00001), hypertension related symptoms (n = 509; RR: 1.31; 95% CI: 1.15 to 1.49; P < 0.0001), and heart rate (n = 138; MD = −2.40 bpm; 95% CI: −4.23 to −0.56; P = 0.01). Beneficial effects but no statistically significant reduction in total cholesterol (n = 138; MD = −0.11 mmol/l; 95% CI: −0.65 to 0.44; P = 0.71), or triglyceride (n = 138; MD = −0.20 mmol/l; 95% CI: −0.46 to 0.07; P = 0.14) was observed in LPAD. Compared with antihypertensive drugs, LDXGD used alone significantly improved systolic BP, diastolic BP, and hypertension related symptoms. But there was no difference between LDXGD and antihypertensive drugs on categorical BP (n = 120; RR: 1.09; 95% CI: 0.96 to 1.23; P = 0.18). The safety of LDXGD were still unclear.Conclusions: Due to poor methodological quality of the included trials, as well as potential reporting bias, our review found no conclusive evidence for the effectiveness of LDXGD in treating hypertension. The potential beneficial effects and safety of LDXGD should be assessed in future properly designed trials.
展开▼
机译:背景: strong>中药经典龙胆泻肝汤(LDXGD)在中国高血压患者中得到广泛应用。目的: strong>该系统评价和荟萃分析旨在评估高血压LDXGD对高血压的疗效和安全性。方法: strong>检索了PubMed,EMBASE,Cochrane对照试验中心登记册,中国生物医学文献数据库,中国科学期刊数据库,中国国家知识基础设施和万方数据库。 2017年2月7日进行了治疗高血压的随机对照试验。结果 strong>:鉴定出9项试验。与降压药相比,龙胆泻肝汤加降压药(LPAD)显着改善了收缩压(BP)(n = 138; MD = −4.82 mmHg; 95%CI:−7.89至−1.76; P = 0.002),舒张压BP( n = 138; MD = -2.42 mmHg; 95%CI:-3.22至-1.62; P <0.00001),类别BP(n = 509; RR:1.26; 95%CI:1.17至1.36; P <0.00001),高血压相关症状(n = 509; RR:1.31; 95%CI:1.15至1.49; P <0.0001)和心率(n = 138; MD = −2.40 bpm; 95%CI:−4.23至−0.56; P = 0.01)。有益效果,但总胆固醇降低(n = 138; MD = -0.11 mmol / l; 95%CI:-0.65至0.44; P = 0.71)或甘油三酸酯(n = 138; MD = -0.20 mmol / 1;在LPAD中观察到95%CI:-0.46至0.07; P = 0.14)。与降压药相比,单独使用LDXGD可以显着改善收缩压,舒张压和高血压相关症状。但是LDXGD和降压药在分类血压上没有差异(n = 120; RR:1.09; 95%CI:0.96至1.23; P em> = 0.18)。 LDXGD的安全性尚不清楚。结论: strong>由于所纳入试验的方法学质量较差,以及潜在的报告偏见,我们的审查未发现LDXGD治疗高血压的确切证据。 LDXGD的潜在有益作用和安全性应在以后适当设计的试验中进行评估。
展开▼